Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM/DOCE in High-risk BCG-naive NMIBC
NCT05671900Active, not recruiting
- Sponsor
- Clinical Hospital Center Zagreb
- Start
- Apr 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gemcitabine and docetaxel in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Clinical Hospital Center Zagreb. Primary endpoint: Recurrence free survival at 2 years. Started Apr 2020; status: active, not recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05671900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671900.